Questions about our services? (USA) 877-735-3648 Outside the US: 001-610-642-6055

September 2016 Newsletter

Tandem gets FDA clearance for remote software update tool

Wouldn't it be great to be able to get a software update to your existing insulin pump when your pump company comes out with new innovations rather than having to wait until your pump is out of warranty and you are due for a new pump? It's frustrating when you want the latest and greatest version but have to wait. Fantasy should be becoming reality sooner than you think.

By |2016-09-16T20:18:02-04:00September 16th, 2016|Categories: September 2016 Newsletter|0 Comments

Improvements in New Microneedle device for Type 2 diabetes

There is some early research on Type 2 patients showing that a novel way of administering insulin may give better insulin coverage of meals and help to provide better after meal blood glucose (BG) control in Type 2 patients. In the future, it's possible that we could all be giving insulin in a different way than we do now. For details, read on!

By |2016-12-08T23:26:36-05:00September 16th, 2016|Categories: September 2016 Newsletter|0 Comments

The Challenge of Diabetes Management & Air Travel

Did you know that about 10% of travelers with diabetes report that they've had a diabetes-related complication during air travel? Let's take a look at some guidance on how to avoid problems with diabetes management during long distance travel.

By |2024-03-25T17:44:25-04:00September 16th, 2016|Categories: September 2016 Newsletter|1 Comment

Finding a diabetes clinical trial just got a whole lot easier

Have you ever wanted to participate in a clinical trial for diabetes so you could play a role in the development of a new product or make a contribution to our body of knowledge about the cure/prevention/treatment of diabetes, but didn't know how to do it? The process is now much more user-friendly than it has ever been!

By |2016-09-16T20:10:54-04:00September 16th, 2016|Categories: September 2016 Newsletter|0 Comments

Incidence of death similar in DCCT/EDIC participants and the general population

The participants in the DCCT's conventional therapy group have significantly higher mortality, but those who had intensive control are faring much better. What does the latest evidence from a study published online on July 13 in Diabetes Care show?

By |2016-09-16T20:12:00-04:00September 16th, 2016|Categories: September 2016 Newsletter|0 Comments
Go to Top